LOTIS-7: A study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

ADC THERAPEUTICS

Scan for more information

Baseline characteristics in the treated population (N=41)[a]

Age, median (range)

71 years (26-85)

Male 56%	Female 44%
≥2 prior therapies 51%	1 prior therapy[b] 49%
de novo DLBCL 73%	HGBCL 14.6% / trFL 9.8% / FL grade 3b 2.4%
No prior CAR-T therapy 80%	Prior CAR-T therapy 20%
ECOG PS 0 56%	ECOG PS 1 42% / ECOG PS 2 2%
Refractory to last therapy 49%	Relapsed after last therapy 49% / Other 2%

[a]Treated population for this presentation includes patients from part 1 and 2 who had received ≥1 dose of the study drug at the 120- or 150-µg/kg dose level and had an LBCL histology. [b]There was a median of 2 prior therapies (range, 1-5).
Data cutoff: April 14, 2025.

Efficacy outcomes, efficacy evaluable population (N=30)[a]

Glofit + Lonca, 120 µg/kg

- ORR: **93.3%** (n=15) 95% CI, 68.1-99.8
- median time to first response: **42.0** days (n=14)
- mDOR: **NE** months[b] (n=14) 95% CI, NE-NE
- CRR: **86.7%** (n=15) 95% CI, 59.5-98.3
- median time to first CR: **80.0** days (n=13)

Glofit + Lonca, 150 µg/kg

- ORR: **93.3%** (n=15) 95% CI, 68.1-99.8
- median time to first response: **42.0** days (n=14)
- mDOR: **NE** months[b] (n=14) 95% CI, NE-NE
- CRR: **86.7%** (n=15) 95% CI, 59.5-98.3
- median time to first CR: **42.0** days (n=13)

[a]The efficacy evaluable population (N=30) included all patients who received ≥1 dose of study drug with a valid baseline and ≥1 valid postbaseline disease assessment. Patients who do not have a postbaseline assessment owing to early clinical progression or death were also included. [b]Efficacy population of responders only.
Data cutoff: April 14, 2025.

Efficacy over time: sustained responses beyond the end of treatment (N=41)



Data cutoff: April 14, 2025.

Safety outcomes, treated population (N=41)[a]

93% Any-grade TEAE

56% Grade ≥3 TEAE

Grade ≥3 TEAE occurring in >5% of patients

- **24%** Neutropenia
- **10%** Anemia
- **7%** GGT increased
- **7%** Thrombocytopenia
- **7%** AST increased

AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; TEAE, treatment emergent adverse event.



[a]Treated population includes patients from part 1 and 2 who had received ≥1 dose of the study drug at the 120- or 150-µg/kg dose level and had an LBCL histology.
Data cutoff: April 14, 2025.

PK and biomarker outcomes

Pharmacokinetics

- Lonca exposure (AUC_{last} and C_{max}) showed a dose-dependent increase in the first 2 cycles
- No post-dose Lonca antidrug antibodies were detected with Lonca + Glofit, indicating low immunogenicity with the combination
- The number of circulating activated T cells (HLA-DR$^+$) increased during treatment (orange and yellow lines)
- Monocytes (CD14$^+$) and natural killer cells (CD3$^-$/CD16$^+$/CD56$^+$) were similarly modulated and showed a trend of increase over time (data not shown)
- Cytokine profiles, assessed by multiplex immunoassay, indicated immune activation as exemplified by IFN-γ (blue line)

Patterns of helper T cells, cytotoxic T cells, and IFN-γ



Data cutoff: April 14, 2025.

Abbreviations
C, cycle; **CAR-T**, chimeric antigen receptor T-cell; **CR**, complete response; **CRS**, cytokine-release syndrome; **D**, day; **DLBCL**, diffuse large B-cell lymphoma; **ECOG PS**, Eastern Cooperative Oncology Group Performance Status; **EOI**, end of infusion; **FL**, follicular lymphoma; **Glofit**, glofitamab; **HGBCL**, high-grade B-cell lymphoma; **HLA-DR**, human leukocyte antigen–DR isotype; **ICANS**, immune-effector cell–associated neurotoxicity syndrome; **IFN-γ**, interferon-gamma; **LBCL**, large B-cell lymphoma; **Lonca**, loncastuximab tesirine; **NE**, not estimable; **ORR**, overall response rate; **PRE**, pretreatment; **PR**, partial response; **SD**, stable disease; **trFL**, transformed follicular lymphoma.

References
1. Alderuccio, JP et al. Presented at: EHA 2025; June 12-15, 2025; Milan, Italy.

ADC THERAPEUTICS